Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)

Annals of Oncology

Volumn 19, Issue 4, 2008, Pages 821-822

  Blay, J Y ^a,b   El Sayadi, H ^b   Thiesse, P ^b   Garret, J ^c   Ray Coquard, I ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c Clinique du Parc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; IMATINIB; PROTEIN TYROSINE KINASE A;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CASE REPORT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR;

EID: 41549158178     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn033     Document Type: Article

References (7)

1. Medenhall WM, Mendenhall CM, Reith JD et al. Pigmented villonodular synovitis, Am J Clin Oncol 2006; 29: 548-550.
2. Martin RC II, Osborne DL, Edwards MJ et al. Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: Defining the presentation, surgical therapy and recurrence. Oncol Rep 2000; 7(2): 413-419.
3. West RB, Rubin BP, Miller MA et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103: 690-695.
4. Cupp JS, Miller MA, Montgomery KD et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 2007; 31: 970-976.
5. Dewar AL, Cambared AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127-3132.
6. Moller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer 2007; In press.
7. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase lll study of Imatinib in patents with advanced gastrointestnal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.